CLAIMS:

1. A compound of Formula (I):

Formula (I)

5

wherein:

A is phenyl or a 5- or 6-membered heteroaryl ring, where A is unsubstituted or substituted by one or 2 groups independently selected from \mathbb{R}^3 ;

R1 is selected from hydrogen and methyl;

10 R² is selected from hydrogen and methyl;

 ${f R}^3$ is selected from methyl, methoxy, fluoro, chloro and cyano; with the proviso that at least one of ${f R}^1$ and ${f R}^2$ is methyl; or a salt, pro-drug or solvate thereof.

- 15 2. A compound of Formula (I) or a salt, pro-drug or solvate thereof, as claimed in Claim 1, wherein R¹ is methyl.
- A compound of Formula (I), as claimed in Claim 1 or Claim 2, which is a compound of Formula (Ia), or a salt, pro-drug or solvate thereof; wherein A and R² are as defined in
 Claim 1.

Formula (Ia)

4. A compound of Formula (Ia), as claimed in Claim 3, which is a compound of Formula25 (Ib), or a salt, pro-drug or solvate thereof.

Formula (Ib)

A compound of Formula (Ia), as claimed in Claim 3, which is a compound of Formula
(Ic), or a salt, pro-drug or solvate thereof;

Formula (Ic)

wherein:

A' is heteroaryl.

10

- 6. A compound of Formula (I), (Ia), (Ib) or (Ic) as claimed in any one of Claims 1 to 5, wherein R² is hydrogen, or a salt, pro-drug or solvate thereof.
- 7. A compound of Formula (I) as claimed in Claim 1, which is a compound of Formula 15 (1e); or a salt, pro-drug or solvate thereof,

Formula (Ie)

wherein:

A is selected from phenyl, thienyl and furanyl;

A is optionally substituted with methyl, methoxy, chloro or fluoro;

R¹ is selected from hydrogen and methyl;

 \mathbb{R}^2 is selected from hydrogen and methyl; with the proviso that at least one of R^1 and R^2 is methyl.

- 8. A compound of formula (I) as claimed in Claim 1, selected from:
- 5 6-{3-[(1S)-1-methyl-2-phenylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3pyridine carboxylic acid;
 - 6-{3-[(1S)-1-methyl-2-furan-2-ylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino} -3-pyridine carboxylic acid;
 - 6-{3-[(1S)-1-methyl-2-(2-methoxyphenyl)ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-
- 10 benzoylamino}-3-pyridine carboxylic acid;
 - 6-{3-[(1S)-1-methyl-2-thien-2-ylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino} -3-pyridine carboxylic acid;
 - 6-{3-[(1S)-1-methyl-2-(5-chlorothien-2-yl)ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]benzoylamino}-3-pyridine carboxylic acid:
- 15 6-{3-[(1S)-1-methyl-2-thien-3-ylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino} -3-pyridine carboxylic acid;
 - $6-\{3-[(1S)-1-methyl-2-(5-methylfuran-2-yl)ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-1-methylethoxy]-1-methylethoxy] 5-[(1S)-1-methyl-2-(5-methylfuran-2-yl)ethoxy]-1-methylethoxy] 5-[(1S)-1-methyl-2-(5-methylfuran-2-yl)ethoxy]-1-methylethoxy] 5-[(1S)-1-methyl-2-(5-methylfuran-2-yl)ethoxy]-1-methylethoxy] 5-[(1S)-1-methylethoxy]-1-methylethoxy] 5-[(1S)-1-methylethoxy]-1-methylethox$ benzoylamino}-3-pyridine carboxylic acid;
 - 6-{3-[(1S)-1-methyl-2-{4-fluorophenyl}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-
- 20 benzoylamino}-3-pyridine carboxylic acid;
 - 6-{3-[(2S)-2-methyl-2-phenylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]benzoylamino}-3-pyridine carboxylic acid;
 - 6-{3-[(2R)-2-methyl-2-phenylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino} -3-pyridine carboxylic acid; and
- $25 \quad 6-\{3-[(1S)-1-methyl-2-\{2-chlorophenyl\}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-1-methylethoxy-1-methyle$ benzoylamino}-3-pyridine carboxylic acid;
 - $6-\{3-[(1S)-1-methyl-2-\{3,5-difluorophenyl\}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-5-[(1S)-2-methyl$ benzoylamino}-3-pyridine carboxylic acid;
 - 6-{3-[(1S)-1-methyl-2-{3-fluorophenyl}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-
- 30 benzoylamino}-3-pyridine carboxylic acid;
 - 6-{3-[(1S)-1-methyl-2-(5-methylthiophen-2-yl)ethoxy]-5-[(1S)-2-methoxy-
 - 1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid:
 - $6-\{3-[(1S)-1-methyl-2-\{3-methoxyphenyl\}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-1-methylethoxy-1-methylethox$

WO 2005/044801 PCT/GB2004/004579
- 50 -

benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-{2-methylphenyl}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

 $6-\{3-[(1S)-1-methyl-2-\{4-methoxyphenyl\}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-1-methylethoxy-1-methylethox$

- 5 benzoylamino}-3-pyridine carboxylic acid;
 - 6-{3-[(1S)-1-methyl-2-(5-chlorofuran-2-yl)ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid; or a salt, pro-drug or solvate thereof.
- 10 9. A pharmaceutical composition comprising a compound of Formula (I) as claimed in any one of Claims 1 to 8, or a salt, solvate or prodrug thereof, together with a pharmaceutically-acceptable diluent or carrier.
- 10. A compound of Formula (I), as claimed in any one of Claims 1 to 8, or a salt, solvate or prodrug thereof, for use as a medicament.
 - 11. A compound of Formula (I), as claimed in any one of Claims 1 to 8, or a salt, solvate or prodrug thereof, for use in the preparation of a medicament for treatment of a disease mediated through GLK, in particular type 2 diabetes.

20

- 12. A method of treating GLK mediated diseases, especially diabetes, by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 8, or a salt, solvate or prodrug thereof, to a mammal in need of such treatment.
- 25 13. The use of a compound of Formula (I), as claimed in any one of Claims 1 to 8, or salt, solvate or pro-drug thereof, in the preparation of a medicament for use in the combined treatment or prevention of diabetes and obesity.
- 14. The use of a compound of Formula (I), as claimed in any one of Claims 1 to 8, or salt, solvate or pro-drug thereof, in the preparation of a medicament for use in the treatment or30 prevention of obesity.

- 15. A method for the combined treatment of obesity and diabetes by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 8, or salt, solvate or pro-drug thereof, to a mammal in need of such treatment.
- 5 16. A method for the treatment of obesity by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 8, or salt, solvate or pro-drug thereof, to a mammal in need of such treatment.
- 17. A process for the preparation of a compound of Formula (I) as claimed in Claim 1, a salt, pro-drug or solvate thereof which comprises:
 - (a) reaction of an acid of Formula (IIIa) or activated derivative thereof with a compound of Formula (IIIb),

Formula (IIIa)

Formula (IIIb),

15 wherein P¹ is H or a protecting group; or

WO 2005/044801

(b) de-protection of a compound of Formula (IIIc),

$$A \longrightarrow P^1$$

$$Q \longrightarrow Q$$

$$Q$$

Formula (IIIc)

wherein P1 is a protecting group; or

20 (c) reaction of a compound of Formula (IIId) with a compound of Formula (IIIe),

Formula (IIId)

Formula (IIIe)

wherein X^1 is a leaving group and X^2 is a hydroxyl group or X^1 is a hydroxyl group and X^2 is a leaving group, and wherein P^1 is a protecting group; or

5 (d) reaction of a compound of Formula (IIIf) with a compound of Formula (IIIg)

$$A \xrightarrow{R^1} X^3$$

$$O \xrightarrow{O} O \xrightarrow{N} O \xrightarrow{N} O$$

Formula (IIIf)

Formula (IIIg)

wherein X^3 is a leaving group and X^4 is a hydroxyl group or X^3 is a hydroxyl group and X^4 is a leaving group; or

10 (e) reaction of a compound of Formula (IIIh) with a compound of Formula (IIIi),

Formula (IIIh)

Formula (IIIi);

wherein X^5 is a leaving group and wherein P^1 is H or a protecting group; and thereafter, if necessary:

- 15 i) converting a compound of Formula (I) into another compound of Formula (I);
 - ii) removing any protecting groups;
 - iii) forming a salt, pro-drug or solvate thereof.